Search

A method of autolymphochemotherapy was developed based on administration of a "therapeutic" course of chemotherapy following cytotoxic treatment of a large amount (1.5-2 l) of central lymph obtained by external drainage of the thoracic duct. Immediate results of treatment of 15 patients with advanced breast, lung (non-small-cell) and ovarian cancer with various degree of chemoresistance are presented. Marked response was observed in 14 cases. It seems justified to use the method for the treatment of locally advanced cancer.

In a non-randomized study the treatment results of 59 patients with disseminated seminoma were evaluated: 21 patients were treated with a VAB-6 combination and 38 with a CP (cyclophosphamide and cisplatin) combination. After VAB-6 CR was observed in 8 patients and 6 achieved CR with additional treatment: 1 with chemotherapy (PVB) and 5 with radiotherapy (RT). The final CR rate was 67%. At a median follow-up of 38 (11-70) months 15 (71%) are alive, and 11 of them (52%) are NED; 6 have died. Of the 38 patients treated with CP alone only 18 achieved CR and 9 had a CR after additional RT and 1 chemotherapy (VAB-6), the overall CR rate was 72%. The median follow-up is 24 (4-55) months, 28 (74%) are alive, 24 (66%) are currently NED, and 9 have died. Both regimens were well tolerated, the main toxicity being leukopenia: 48% (WHO grade 111-1V-5%) for VAB-6, and 59% (13%) for CP. Hearing loss was registered in 8 patients receiving CP and in 2 receiving VAB-6. There were no fatal toxicities. Thus, VAB-6 and CP regimens seem to have compatible and high activity in disseminated seminoma.

Preliminary results of chemoradiotherapy in 30 patients with the larynx cancer T3T4N0M0 are presented. Two treatment schemes were applied. According to scheme I, the treatment was started with chemotherapy with 5-fluorouracil in doses of 1000 mg on days 1, 2 and 3, bleomycetin in doses of 15 mg on days 1, 2 and 3 and platidiam in doses of 120 mg/m2 on day 4 followed by radiotherapy to the total dose of 66 to 70 Gy. Scheme II included two analogous courses of the chemotherapy, one prior to the radiotherapy and the other after irradiation in a dose of 38 to 40 Gy, after a two-week interval the radiotherapy was continued to doses of 66 to 70 Gy. 15 patients were treated in accordance with each scheme. Complete resorption of the tumor was observed in 66.6 and 83.3 per cent of the patients treated according to schemes I and II, respectively. The results showed that the use of 5-fluorouracil, bleomycetin and platidiam in combination with radiotherapy was promising in treatment of patients with local cancer of the larynx.

Clinical trials of bleomycetin and platidiam combination were carried out in 13 patients with disseminated melanoma of the skin. Two regimens of the treatment were used. Regimen I included intravenous administration of platidiam in a dose of 20 mg/m2 with a water load on days 2, 3, 4, 5 and 6 of the treatment course and intravenous administration of bleomycetin in a dose of 30 mg/m2 on days 1 and 7. The intervals between the courses consisted of 4 weeks. Regimen II included the use of platidiam in a dose of 20 mg/m2 administered as 6-hour intravenous infusions in 1.2 1 of isotonic sodium chloride solution daily for 5 days. On the first day of this cycle bleomycetin was administered intravenously in a dose of 30 mg/m2. The cycles were performed during the 1st and the 3rd weeks of the treatment course. During the 2nd and the 4th weeks platidiam was administered in a dose of 40 mg/m2 once a week and bleomycetin was administered intramuscularly in a dose of 6 mg/m2 daily for 5 days. A more than 50 per cent decrease in the tumor formation was observed in 38 per cent of the patients. The combination had no toxic effect on hemopoiesis and may be used in new programs on chemotherapy of disseminated melanoma of the skin.

The data on the treatment of 19 patients with squamous cell carcinoma of different sites are presented. A combination of chemotherapeutics, including methotrexate, adriamycin and bleomycin was used. The combination was effective and low toxic. It may be recommended for the treatment of the above form of carcinoma.

Efficacy and toxicity of VAB-6 combinations with bleomycin, bleomycetin or peplomycin were studied in treatment of 77 patients with metastases of germ-cell tumors: testicle tumors in 71 patients and extragonadal tumors in 6 patients. After the chemotherapy complete regression was observed in 37 patients (48.7 per cent). In 44 patients (57.1 per cent) residual metastases after the chemotherapy were resected. The frequency of complete regression after using the VAB-6 combinations with bleomycin, bleomycetin and peplomycin amounted to 58.8, 61.5 and 47.1 per cent respectively. The treatment results depended on the disease extent. When the disease extent was minimal complete regression was observed in 87.5 per cent of the patients. The respective figures for the disease moderate and significant extents were 66.7 and 37.8 per cent. During the average observation period of 22.1 months (7-40 months) 39 patients survived and had no signs of the disease. The combinations markedly differed in their toxicity.

The experience gained in the treatment of 111 cases of testicular tumor is summarized in the paper. Methods of management of testicular cancer in the eighties differ significantly from those employed in the seventies. A set of drugs used is different. The share of cases of monochemotherapy has decreased markedly. PVB and VAB-6 schemes are highly effective inducing complete or partial remission in 80-90% of cases. Issues of treatment of patients with massive metastases in retroperitoneal lymph nodes and lungs remain unresolved. Timely diagnosis of dissemination will improve chemotherapy results.

Thirty-seven patients were treated for advanced malignant testicular tumors with combined chemotherapy including cis-platinum (Platidiam). A complete regression was achieved in 23 patients (62%). No severe side effects were observed. Also in this study the effectivity of cis-platinum in the treatment of testicular tumors was proved.

The results of treatment of 69 cases of advanced soft tissue sarcomas are presented. Patients were given various drug schemes including cisplatin. Overall response in the study group was 30%. Tumor appeared sensitive to the treatment in 49%. A combination of carminomycin, methotrexate, cyclophosphamide and cisplatin proved to be the most effective (39%). The scheme was effective in both untreated patients and those previously treated with adriamycin. Hematologic toxicity registered in 67% cases was the most severe complication involved in the treatment with the above drug regimen.